ESPE2016 Rapid Free Communications Growth: Clinical (8 abstracts)
A Hybrid Fc-fused Human Growth Hormone, GX-H9, Shows a Potential for Weekly and Semi-monthly Administration in Clinical Studies
EunJig Lee a , Jochen Schopohl b , Aryaev Mykola c , Tae Kyung Kim d , Young-Joo Ahn e , Jung-Won Woo d , Woo Ick Jang e , Young-Chul Sung d & H. Michael Keyoung d
aYonsei University, Seoul, Republic of Korea; bUniversity of Munich Medizinsche Klinik, Munich, Germany; cInstitue of Endocrinology and Metabolism named after Komisarenko NAMS of Ukraine, Kyev, Ukraine; dGenexine, Inc., Seongnam, Republic of Korea; eHandok, Inc., Seoul, Republic of Korea
Background, Objective and hypotheses: GX-H9 is a hybrid Fc-based long-acting recombinant human growth hormone (hGH). The safety, tolerability, and PK/PD of single ascending dose in healthy volunteers were assessed to determine GX-H9 doses capable of normalizing IGF-1 level. The PK/PD, safety, efficacy and tolerability of multiple sequential doses of GX-H9 in adult growth hormone deficiency (AGHD) were compared to that of a daily recombinant hGH in AGHD. A Phase 2 study in pediatric GHD (PGHD) is also ongoing to investigate safety, efficacy and PK/PD of GX-H9.
Method: A double-blind, randomized, placebo-controlled, single ascending dose Phase 1 study of GX-H9 was conducted in 4 groups of healthy subjects (n=32) with four sequential dose levels (0.2, 0.4, 0.8 or 1.6 mg/kg). Currently, a Phase 2, randomized, active-controlled, open-label, sequential dose study of GX-H9 (0.1 mg/kg per weekly, 0.2 and 0.3 mg/kg per semi-monthly) is being conducted in patients with AGHD (n=45). In addition, a Phase 2, randomized, active-controlled, open-label, multiple dose study of GX-H9 with weekly and semi-monthly administrations is being conducted in patients with PGHD (n=48).
Results: Single doses of GX-H9 in the range of 0.2 to 1.6 mg/kg were well tolerated at all dose levels. Only mild adverse events were observed and no lipoatrophy or anti-drug antibodies were detected. Geometric mean of t1/2 ranged between 69.2 and 138.0 hours. IGF-1 serum concentrations increased in a dose-dependent manner between 0.2 and 1.6 mg/kg. The interim Phase 2 results have indicated that AGHD patients (n=11) receiving the lowest dose of GX-H9 (0.1 mg/kg) weekly for 12 weeks were safe and comparable with those receiving 6 μg/kg of Genotropin® daily for 12 weeks (n=2) in the mean increases in IGF-1 (101.3±31.2 ng/mL vs 109.1±45.0 ng/mL, respectively). The administration of higher doses showed potential for semi-monthly treatment of GX-H9 in AGHD and PGHD.
Conclusion: Phase 1 and interim Phase 2 results have demonstrated that GX-H9 is safe and well tolerated in healthy subjects and in patients with AGHD and PGHD. The data from ongoing Phase 2 studies will be presented in addition to the Phase 1 result.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more